Pirfenidone treatment attenuates fibrosis in autosomal dominant polycystic kidney disease
Viji Remadevi, Abeda Jamadar, Meekha M. Varghese, Haichun Yang, Sumedha Gunewardena, Darren P. Wallace, Reena Rao · 2026
Read Pirfenidone treatment attenuates fibrosis in autosomal dominant polycystic kidney disease by Viji Remadevi, Abeda Jamadar, Meekha M. Varghese, Haichun Yang, Sumedha Gunewardena, Darren P. Wallace, Reena Rao (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13596711.txt.
Description
Viji Remadevi and colleagues tested pirfenidone, a drug approved against lung scarring, in autosomal dominant polycystic kidney disease, where growing cysts are joined by progressive scarring that itself drives kidney failure. Their study began with single-nucleus sequencing of human polycystic kidneys to find where the scar material comes from.
Fibroblast cells proved to be the dominant source of fibrous matrix, and in cultured human disease cells pirfenidone quieted matrix genes and slowed growth, movement, and contraction. In a mouse model of the disease the drug reduced scarring, matrix buildup, and the scar-forming cell population, and kidney function improved. Kidneys grew less enlarged, though cyst counts fell only in females. The authors position pirfenidone as a partner to cyst-targeted drugs, arguing the scar deserves treatment in its own right.
Catalog record
| CREATOR | Viji Remadevi, Abeda Jamadar, Meekha M. Varghese, Haichun Yang, Sumedha Gunewardena, Darren P. Wallace, Reena Rao |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 37 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |